Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates

Immatics Announces First Quarter 2026 Financial Results and Business Update

All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

SG Americas Securities LLC Makes New Investment in Immatics N.V. $IMTX

Immatics N.V. (NASDAQ:IMTX) Receives $19.00 Average PT from Analysts

Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot

Immatics (NASDAQ:IMTX) Trading Down 5% – Here’s What Happened

Immatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of “Moderate Buy” from Analysts

Immatics (NASDAQ:IMTX) Stock Price Up 3.9% – Should You Buy?

Immatics: PRAME Leader's Transition To Commercial Reality

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Immatics Announces $125 Million Underwritten Offering

Immatics (NASDAQ:IMTX) Sets New 12-Month High – Here’s What Happened

Immatics N.V. (NASDAQ:IMTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

Immatics Announces Third Quarter 2025 Financial Results and Business Update

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

Immatics Appoints Amie Krause as Chief People Officer

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

Immatics: Multiple Clinical Catalysts In Q4'25 And 2026

New Strong Sell Stocks for August 15th

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

Immatics Announces Second Quarter 2025 Financial Results and Business Update

Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

Immatics Announces First Quarter 2025 Financial Results and Business Update

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Immatics N.V.: Trading Below Cash, But Not Without Reason

Immatics Announces Full Year 2024 Financial Results and Business Update

New Strong Buy Stocks for February 12th

New Strong Buy Stocks for January 9th

Immatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock?

What Makes Immatics (IMTX) a New Buy Stock

Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?

Immatics: A Promising TCR Pipeline

Immatics Announces Pricing of $150 Million Public Offering

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

Immatics Announces Proposed $150 Million Public Offering

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024